Lisata Therapeutics reports FY2022 financial results and provides business update

LISATA THERAPEUTICS, INC.

Net loss for FY2022 was $54.2 million, including $30.4 million non-routine merger-related IPR&D expense.
Cash, cash equivalents and marketable securities totaled $69.2 million as of December 31, 2022.
LSTA1 Phase 2b ASCEND study in pancreatic cancer is ongoing; basket trial in other solid tumors planned for H1 2023.
HONEDRA for critical limb ischemia is in pre-consultation with Japan's PMDA; partner search continues.
XOWNA development suspended; LSTA201 proof-of-concept study did not show consistent kidney function improvement.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LISATA THERAPEUTICS, INC. reported financial results for three and twelve months ended December 31, 2022.

Period: three and twelve months ended December 31, 2022
Result: reported results

Exact text from the filing

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, NJ (March 30, 2023) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-23-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.